Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI324 Dose Escalation in Diabetic Macular Edema
NCT05489718Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI324 in diabetic macular edema (DME) (5 arms), sponsored by Innovent Biologics. Primary endpoint: Safety evaluation indicators at 24 weeks. Started Aug 2022; status: completed.
02
Drugs
IBI324
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05489718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489718.